Verve Therapeutics, Inc. logo

Verve Therapeutics, Inc. (VERV)

Delisted
25 Jul 2025
NASDAQ (NGS) NASDAQ (NGS)
$
11. 13
+0.03
+0.2703%
Pre Market
$
11. 22
+0.09 +0.8086%
994.04M Market Cap
- P/E Ratio
- Div Yield
10.31M Volume
-2.93 Eps
$ 11.1
Previous Close
Investors:
Day Range
11.13 11.13
Year Range
2.87 11.4
Want to track VERV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 1 year ago
Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ:VERV). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Accesswire | 1 year ago
Verve Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Encouraged To Contact The Schall Law Firm

Verve Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Encouraged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

Accesswire | 1 year ago
Levi & Korsinsky Reminds Verve Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV

Levi & Korsinsky Reminds Verve Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 1 year ago
Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 1 year ago
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESSWIRE / October 1, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve Therapeutics" or "the Company") (NASDAQ:VERV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period").

Accesswire | 1 year ago
Shareholders that lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV

Shareholders that lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 1 year ago
Shareholders of Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Shareholders of Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 1 year ago
Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 1 year ago
Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / If you suffered a loss on your Verve Therapeutics, Inc. (NASDAQ:VERV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 1 year ago
The Schall Law Firm Urges Investors To Take Part In A Securities Fraud Case Against Verve Therapeutics, Inc.

The Schall Law Firm Urges Investors To Take Part In A Securities Fraud Case Against Verve Therapeutics, Inc.

LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

Accesswire | 1 year ago
Loading...
Load More